ArticleDiscover oncology2025
Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.Breast cancer research : BCR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrognostic factors for special types of breast cancer remain poorly understood owing to limited clinical research. Therefore, we evaluated the prognostic significance of the maximum standardized uptake value (SUVmax) derived from fluorodeoxyglucose positron emission tomography/computed tomography in patients with special types.
methodsThis retrospective cohort study included patients who underwent curative surgery for special types of breast cancer at Hiroshima University Hospital between 2006 and 2021. Pretreatment SUVmax values, with a cutoff of > 3.0, were evaluated.
resultsAmong the 226 identified cases, 105 with favorable histology according to the NCCN guideline were excluded, leaving 121 cases for analysis. The patients had a median follow-up period of 77.8 months (IQR 37.2-114.3). SUVmax > 3.0 was significantly associated with advanced T and N stages, higher nuclear grade, and receipt of adjuvant chemotherapy (P = 0.012, P = 0.006, P < 0.005, P < 0.005, respectively). The 5-year relapse-free survival (RFS) and overall survival (OS) rates were 82.8% and 89.2% for SUVmax > 3.0 and 94.6% and 96.7% for SUVmax ≤ 3.0 (P = 0.005; P = 0.167, respectively). Multivariate analysis identified N stage (Hazard Ratio (HR) 4.20, 95% CI 1.18-14.9, P = 0.026) and SUVmax (HR 3.55, 95% CI 1.12-11.2, P = 0.026) as significant independent prognostic factors for RFS, while no factors were prognostic for OS.
conclusionsOur results underscore the utility of SUVmax > 3.0, which is a potential prognostic indicator of poor outcomes in patients with special types of breast cancer, in guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.